RESUMO
Dual inhibition of fatty acid binding proteins 4 and 5 (FABP4 and FABP5) is expected to provide beneficial effects on a number of metabolic parameters such as insulin sensitivity and blood glucose levels and should protect against atherosclerosis. Starting from a FABP4 selective focused screening hit, biostructure information was used to modulate the selectivity profile in the desired way and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. With very good pharmacokinetic properties and no major safety alerts, compound 12 was identified as a suitable tool compound for further in vivo investigations.
Assuntos
Proteínas de Ligação a Ácido Graxo/antagonistas & inibidores , Sequência de Aminoácidos , Animais , Desenho de Fármacos , Proteínas de Ligação a Ácido Graxo/química , Camundongos , Camundongos Knockout , Farmacocinética , Conformação Proteica , Homologia de Sequência de AminoácidosAssuntos
Carnitina O-Palmitoiltransferase/metabolismo , Metabolismo Energético/efeitos dos fármacos , Animais , Carnitina/análogos & derivados , Carnitina/farmacologia , Carnitina/uso terapêutico , Carnitina O-Palmitoiltransferase/antagonistas & inibidores , Carnitina O-Palmitoiltransferase/deficiência , Domínio Catalítico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Ativadores de Enzimas/farmacologia , Ativadores de Enzimas/uso terapêutico , Óxido de Etileno/análogos & derivados , Óxido de Etileno/farmacologia , Óxido de Etileno/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Insuficiência Cardíaca/metabolismo , Humanos , Resistência à Insulina , Isoenzimas/antagonistas & inibidores , Isoenzimas/deficiência , Isoenzimas/metabolismo , Metabolismo dos Lipídeos/efeitos dos fármacos , Isquemia Miocárdica/tratamento farmacológico , Isquemia Miocárdica/metabolismo , Especificidade de Órgãos , Conformação Proteica , Homologia de Sequência de Aminoácidos , EstereoisomerismoRESUMO
Liquid chromatography (LC)-solid-phase extraction (SPE)-nuclear magnetic resonance (NMR)-mass spectrometry (MS) coupling is a key technology for fast and thorough structure elucidation of valuable mass-limited samples. Laborious serial isolation and purification procedures of metabolites, byproducts or impurities from complex biomatrices, natural product extracts or other mixtures of several components can be circumvented by the use of this integrated modular system. This combination of high-end analytical technology significantly accelerates the structure-elucidation process for valuable samples present in minute quantities in mixtures. The information depth is significantly increased by the concurrent availability of NMR and MS data of one chromatographic peak. Thus, this flexible technique is well on its way to becoming the gold standard in analytical chemistry of mixtures. LC-SPE-NMR-MS overcomes the limitations of directly coupled LC-NMR. Full flexibility regarding chromatographic conditions and NMR acquisition is gained by this modular technique. LC-SPE-NMR-MS allows for a rapid structure-elucidation process that would not be possible on the basis of MS or NMR data alone.
Assuntos
Preparações Farmacêuticas/análise , Preparações Farmacêuticas/metabolismo , Cromatografia Líquida , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Preparações Farmacêuticas/química , Extração em Fase SólidaRESUMO
Detailed information on the metabolic fate of lead compounds can be a powerful tool for an informed approach to the stabilization of metabolically labile compounds in the lead optimization phase. The combination of high performance liquid chromatography (HPLC) with nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) has been used to give comprehensive structural data on metabolites of novel drugs in development. Recently, increased automation and the embedding of on-line solid-phase extraction (SPE) into a integrated LC-SPE-NMR-MS system have improved enormously the detection limits of this approach. The new technology platform allows the analysis of complex mixtures from microsome incubations, combining low material requirements with relatively high throughput. Such characteristics make it possible to thoroughly characterize metabolites of selected compounds at earlier phases along the path to lead identification and clinical candidate selection, thus providing outstanding guidance in the process of eliminating undesired metabolism and detecting active or potentially toxic metabolites. Such an approach was applied at the lead identification stage of a backup program on metabotropic glutamate receptor 5 (mGlu5) allosteric inhibition. The major metabolites of a lead 5-aminothiazole-4-carboxylic acid amide 1 were synthesized and screened, revealing significant in vitro activity and possible involvement in the overall pharmacodynamic behavior of 1. The information collected on the metabolism of the highly active compound 1 was pivotal to the synthesis of related compounds with improved microsomal stability.
Assuntos
Aminopiridinas/metabolismo , Microssomos Hepáticos/metabolismo , Preparações Farmacêuticas/metabolismo , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Tiazóis/metabolismo , Regulação Alostérica , Aminopiridinas/síntese química , Cromatografia Líquida de Alta Pressão/métodos , Humanos , Concentração Inibidora 50 , Espectroscopia de Ressonância Magnética/métodos , Espectrometria de Massas/métodos , Microssomos Hepáticos/química , Oxirredução , Preparações Farmacêuticas/síntese química , Receptor de Glutamato Metabotrópico 5 , Extração em Fase Sólida/métodos , Estereoisomerismo , Tiazóis/síntese químicaRESUMO
Optimization of affinity and microsomal stability led to identification of the potent, metabolically stable fenobam analog 4l. Robust in vivo efficacy of 4l was demonstrated in four different models of anxiety. Additionally, a ligand based pharmacophore alignment of fenobam and MPEP is proposed.
Assuntos
Imidazóis/química , Imidazóis/farmacologia , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Animais , Ansiolíticos/síntese química , Desenho de Fármacos , Humanos , Ligantes , Piridinas/química , Receptor de Glutamato Metabotrópico 5 , Relação Estrutura-AtividadeRESUMO
A novel class of potent and stable mGlu5 receptor antagonists was developed by combining information from a high-throughput screening campaign with the structure of the known anxiolytic fenobam. Representative compounds from this class show favorable pharmacokinetic properties and are active in an in vivo model of anxiety.
Assuntos
Ansiolíticos/síntese química , Benzoxazóis/síntese química , Benzoxazóis/farmacocinética , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Animais , Ansiolíticos/administração & dosagem , Ansiolíticos/farmacocinética , Ansiedade/tratamento farmacológico , Benzoxazóis/administração & dosagem , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos/métodos , Imidazóis/química , Modelos Animais , Farmacocinética , Ligação Proteica , Ratos , Receptor de Glutamato Metabotrópico 5 , Relação Estrutura-AtividadeRESUMO
A novel class of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-ones have been discovered and developed as potent and selective GlyT1 inhibitors. The molecules are devoid of activity at the GlyT2 isoform and display excellent selectivities against the mu opioid receptor as well as the nociceptin/orphanin FQ peptide (NOP) receptor. A novel, straightforward and efficient synthetic strategy for the assembly of the target molecules is also presented.
Assuntos
Proteínas da Membrana Plasmática de Transporte de Glicina/antagonistas & inibidores , Peptídeos Opioides/química , Peptídeos/química , Canais de Potássio Corretores do Fluxo de Internalização Acoplados a Proteínas G/química , Humanos , Concentração Inibidora 50 , Modelos Químicos , Isoformas de Proteínas , Receptores de N-Metil-D-Aspartato/química , Receptores Opioides/química , Estereoisomerismo , Raios X , NociceptinaRESUMO
Screening of the Roche compound library led to the identification of cis-N-(2-phenyl-cyclohexyl)-spiropiperidine 1 as structurally novel GlyT1 inhibitor. The SAR, which was developed in this series, resulted in the discovery of highly potent compounds displaying excellent selectivity against the GlyT2 isoform.
Assuntos
Proteínas da Membrana Plasmática de Transporte de Glicina/antagonistas & inibidores , Piperidinas , Compostos de Espiro , Avaliação Pré-Clínica de Medicamentos , Humanos , Conformação Molecular , Piperidinas/química , Piperidinas/classificação , Piperidinas/farmacologia , Compostos de Espiro/química , Compostos de Espiro/classificação , Compostos de Espiro/farmacologia , Relação Estrutura-AtividadeRESUMO
During SAR exploration of N-(2-aryl-cyclohexyl) substituted spiropiperidine as GlyT1 inhibitors, it was found that introduction of an hydroxy group in position 2 of the cyclohexyl residue considerably improves the pharmacological profile. In particular, reduction of the binding affinity at the nociceptin/orphanin FQ peptide and the mu opioid receptors was achieved.